GHRP-1.
GHRP-1 is a synthetic heptapeptide, one of the earliest growth hormone-releasing peptides (GHRPs) developed by Cyril Bowers' group in the 1980s and 1990s alongside GHRP-2 and GHRP-6.
GHRP-1 is a synthetic heptapeptide, one of the earliest growth hormone-releasing peptides (GHRPs) developed by Cyril Bowers' group in the 1980s and 1990s alongside GHRP-2 and GHRP-6. GHRP-1 is research / preclinical, and PepCue grades its published evidence D tier (38/100). Also known as growth hormone-releasing peptide-1. This is a research reference, not medical or dosing advice.
What it is
GHRP-1 is a synthetic heptapeptide, one of the earliest growth hormone-releasing peptides (GHRPs) developed by Cyril Bowers' group in the 1980s and 1990s alongside GHRP-2 and GHRP-6. It is a growth hormone secretagogue, meaning it prompts the pituitary to release the body's own GH rather than being a form of GH itself. It predates the discovery of ghrelin and was one of the pharmacological tools that led researchers to the growth hormone secretagogue receptor (GHS-R1a). It has always been a research compound and was never developed into an approved drug.
How it works
GHRP-1 acts as an agonist at GHS-R1a, the receptor later identified as the endogenous ghrelin receptor, which is expressed in the pituitary and hypothalamus. This is a pathway distinct from growth hormone-releasing hormone (GHRH); GHRPs raise GH through a dual action on somatotrophs and on hypothalamic somatostatin and GHRH tone. Because GHRPs were synthesized before ghrelin was identified in 1999, they are best understood as synthetic ghrelin-mimetic secretagogues. The acute receptor mechanism is well characterized in animals and in short human pituitary-response studies.
Mechanism pathways
Acting on the ghrelin / GH-secretagogue receptor, a pathway separate from GHRH.
The growth hormone secretagogue receptor, GHS-R1a, is a G-protein-coupled receptor expressed on pituitary somatotrophs and in hypothalamic nuclei. Its natural ligand is ghrelin, the stomach-derived hormone associated with hunger. Activation raises growth hormone through a route entirely separate from GHRH: it acts directly on somatotrophs, and it also suppresses hypothalamic somatostatin tone, effectively releasing the brake at the same time as pressing the accelerator. This dual action is why compounds at this receptor and GHRH analogs are often studied together, since combining them produces a larger growth hormone response than either produces alone. The history here is unusual. The synthetic peptides in this group were developed in the 1980s and 1990s by working backwards from observed growth hormone release, years before ghrelin itself was identified in 1999. They were the pharmacological tools that led researchers to the receptor. They are therefore best understood as synthetic ghrelin mimetics that happened to be discovered before the hormone they mimic. Members of this group differ chiefly in selectivity, which is the practical distinction that matters most. GHS-R1a activation is not confined to growth hormone. Because the receptor sits on cells that also govern prolactin and adrenocorticotropic hormone release, and because ghrelin signalling drives appetite and influences gastric motility, several of these compounds raise cortisol and prolactin and increase hunger alongside the intended growth hormone effect. Others were specifically designed to avoid that, producing a comparatively clean growth hormone response with minimal spillover onto the other axes. Some also show additional activity at the CD36 receptor, which has been studied in cardiac contexts. Honest assessment of clinical relevance: the acute receptor pharmacology is well characterised, including in short human studies where growth hormone reliably rises after administration. That is proof of mechanism. What does not exist for this class is proof of benefit. No compound in this group is an approved medicine, controlled trials of sustained use with body composition or clinical endpoints are essentially absent, and material sold under these names is unregulated research-grade product of uncertain content. Growth hormone secretagogues are also prohibited in sport by anti-doping authorities. A further consideration specific to this receptor is desensitisation: sustained agonism at a G-protein-coupled receptor commonly reduces its responsiveness over time, so the acute hormonal response observed in a short study is not a reliable guide to what happens with continued use.
The evidence
The GH-releasing activity of GHRP-1 in humans was documented early. Laron, Bowers and colleagues reported in Acta Endocrinologica (1993, PMID 8279223) that intravenous GHRP-1 produced dose-related rises in plasma GH in children and adolescents. That study was an acute endocrine-challenge design: small numbers of participants, single administrations, GH sampled over a few hours, no placebo comparison and no blinding, and no follow-up beyond the sampling window. It answers one question, whether the pituitary responds, and no others. Bowers' wider body of work defined the GHRP class and its combined pituitary and hypothalamic actions, showing that GHRPs act through a receptor separate from the GHRH receptor and that the two stimuli are synergistic when given together. Those experiments formed the pharmacological trail that led to the cloning of GHS-R1a and then to the identification of ghrelin as its natural ligand in 1999 (PMID 10604470). GHRP-1 specifically has far less human data than its siblings GHRP-2 and GHRP-6, and most of its literature consists of acute endocrine-response and animal experiments. GHRP-2 and GHRP-6 accumulated repeat-administration studies, diagnostic use in the assessment of GH deficiency, and observations on appetite and body composition. Ipamorelin, developed later in the same class, was characterized as a more selective secretagogue that raises GH with less accompanying cortisol and prolactin release (PMID 9849822). Nothing comparable exists for GHRP-1, which was largely bypassed once its siblings and then ghrelin itself became the preferred research tools. What is not known is most of it. There are no controlled trials of chronic GHRP-1 use, body composition, or clinical outcomes. There is no published human pharmacokinetic profile for the compound as it is sold, no bioavailability data for routes other than the intravenous administration used in the original studies, no dose-response work extending past the acute GH peak, and no evidence on whether pituitary responsiveness is sustained or subject to tachyphylaxis with repeated exposure. The evidence amounts to proof of mechanism rather than proof of benefit.
The evidence, in brief
One of the original growth hormone-releasing peptides from Bowers' lab, acting at GHS-R1a (later identified as the ghrelin receptor). Human data are confined to acute GH-response studies, such as the 1993 report of dose-related GH rises in children and adolescents; there are no controlled trials of sustained use, body composition, or clinical outcomes. It has never been approved anywhere and is prohibited in sport by WADA.
- GH-releasing activity of GHRP-1 in children and adolescentsActa Endocrinol (Copenh), 1993 (PMID 8279223)
- PubMed search: GHRP-1 growth hormone-releasing peptidePubMed / NCBI
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #022
Mostly preclinical or mechanistic; little human data.
Some early human evidence exists but isn't definitive.
Claim receipts
Popular claims about GHRP-1, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Acute pituitary response was documented, but in small, unblinded, single-administration endocrine-challenge studies.
No controlled trial of repeated use or body composition has been published.
It has far less human data than GHRP-2 and GHRP-6 and was largely bypassed as a research tool.
Class members raise cortisol and prolactin; where this one sits was never mapped in a dedicated human study.
Safety profile
Acute administration in the early studies was generally tolerated, but there is no long-term human safety data for GHRP-1. As a GH secretagogue it carries the same theoretical concerns as sustained GH elevation, including insulin resistance and fluid retention, and some GHRPs also raise cortisol and prolactin. Those class effects are documented rather than hypothetical: GHRP-2 and GHRP-6 both stimulate ACTH and cortisol release to a degree that ipamorelin was specifically engineered to avoid, and GHRP-6 is a strong appetite stimulant acting through the same ghrelin receptor. Where GHRP-1 sits on that spectrum has never been mapped in a dedicated human study. The recognized consequences of prolonged growth hormone excess, drawn from acromegaly and from supraphysiological GH use, include carpal tunnel symptoms, arthralgia, peripheral edema, worsened glucose tolerance, and cardiac hypertrophy. None of these have been studied for GHRP-1, because no chronic exposure trial exists. Formal toxicology and carcinogenicity packages for the compound are not present in the public literature, and immunogenicity has not been assessed. A legitimate trial would require serial IGF-1 measurement, fasting glucose and insulin or an oral glucose tolerance test, cortisol and prolactin monitoring, thyroid function testing, and periodic assessment for fluid retention and joint symptoms. None of that monitoring occurs outside a clinical setting. Product sold online as GHRP-1 is unregulated research-grade material of uncertain identity and purity, so a vial may contain a different secretagogue, a degraded or truncated peptide, or residual endotoxin and synthesis solvents, and independent testing of the grey peptide market has repeatedly found mislabeled contents. Its human safety profile is largely uncharacterized.
Compound notes
- GHRP-1 is a synthetic heptapeptide, one of the original growth hormone-releasing peptides developed by Cyril Bowers' group in the 1980s and 1990s alongside GHRP-2 and GHRP-6.
- It is a secretagogue rather than a form of GH: it acts as an agonist at GHS-R1a, the receptor later identified as the ghrelin receptor, prompting the pituitary to release the body's own GH.
- It predates ghrelin's 1999 discovery and was one of the pharmacological tools that helped map the secretagogue receptor.
- Human data is limited mainly to acute GH-response studies; there are no controlled trials of chronic use, body composition, or clinical outcomes.
All three are ghrelin-mimetic secretagogues from the same lab, but GHRP-1 has far less human data than its better-studied siblings.
- Never approved by any regulator; research-use-only and prohibited in sport by WADA.
- No long-term human safety data. As a GH secretagogue it carries the theoretical concerns of sustained GH elevation, and some GHRPs also raise cortisol and prolactin.
- Material sold online is unregulated, with uncertain identity and purity.
Regulatory status
GHRP-1 has never been approved by the FDA or any major regulator for any indication. It is a research chemical sold only for laboratory use. As a growth hormone secretagogue it is prohibited in sport by WADA.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Synthetic heptapeptide; one of the original GHRPs from Bowers' lab
- 02Agonist at GHS-R1a, the ghrelin receptor, not a form of GH itself
- 03Predates ghrelin's 1999 discovery and helped map the secretagogue receptor
- 04Human data limited mainly to acute GH-response studies (PMID 8279223)
- 05No approved therapeutic use; research-use-only status
- 06Prohibited in sport by WADA as a GH secretagogue
GHRP-1: research formats
Choose the format you are researching to see route-specific notes.
Same GHRP-class format as GHRP-2 and GHRP-6; the original human studies used the IV route.
GHRP-1 is one of the original growth hormone-releasing peptides from Bowers' lab and is sold today only as a research-grade lyophilized vial, commonly 5 mg. Reconstituting 5 mg with 2.0 mL BAC water gives 2,500 mcg/mL, the same concentrated format used for its better-known siblings GHRP-2 and GHRP-6.
The published human work on GHRP-1 (Laron and Bowers, 1993) used intravenous administration in an acute pituitary-response setting, not repeated subcutaneous use. There are no controlled trials of chronic GHRP-1 administration by any route.
GHRP-1 has far less human data than GHRP-2 or GHRP-6, and material sold online is unregulated research-grade product of uncertain identity and purity.
Sources
Every factual claim above resolves to a real, published source.
- GH-releasing activity of GHRP-1 in children and adolescentsActa Endocrinol (Copenh), 1993 (PMID 8279223)
- PubMed search: GHRP-1 growth hormone-releasing peptidePubMed / NCBI
- Ghrelin is a growth-hormone-releasing acylated peptide from stomachNature, 1999 (PMID 10604470)
- Ipamorelin, the first selective growth hormone secretagogueEur J Endocrinol, 1998 (PMID 9849822)
- PubMed search: growth hormone secretagogue receptor GHS-R1a pituitaryPubMed / NCBI
Cite this page
PepCue. “GHRP-1: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/ghrp-1.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.